AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$REGN

Raymond James raises Regeneron stock price target to $1,020 on strong quarter

Raymond James raised its price target for Regeneron (NASDAQ:REGN) to $1,020, citing strong Q3 2026 performance and positive drug developments. The stock trades at $928 with a $92.4B market cap. Dupixent and Eylea HD are key growth drivers. Regeneron reported Q3 2026 earnings of $20.07 per share and revenue of $5.12B, exceeding estimates. 10 analysts revised earnings upwards. The company holds $16.2B in cash and projects $26B by year-end 2027.

Original reporting
investing.com
Published Oct 30, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The price‑target raise adds fresh bullish momentum beyond the earnings release.

02

Market read

Analyst upgrade could drive short‑term buying interest in REGN.

03

What to watch

Potential competition in the antibody space could temper growth.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Regeneron reported strong Q3 2026 results, beating expectations, and analysts are raising targets.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Raymond James raised its price target on Regeneron to $1,020, indicating a fresh bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target increase reflects confidence in upcoming catalysts and strong Q3 results.

Market effects

Sector

Biotech sector may see modest lift as Regeneron's outlook improves.

Regional

US biotech stocks could benefit from the positive sentiment.

Global

Limited to investors tracking US pharma and biotech equities.

Counterpoint

What could challenge this read

Target may be overly optimistic if upcoming trial data disappoints.

Key entities

  • analyst
    Raymond James

    Equity research firm raising Regeneron's price target.

  • company
    Regeneron Pharmaceuticals

    Biotech firm with strong Q3 performance.

Read at source← All news

Related articles

OCT 30
$REGNHighAI 8/10

REGN Stock Climbs As Libtayo Data And Targets Rise

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock rose 12.06% after positive trial data for Libtayo showed a 37% reduction in death risk. The company reported $4.29B in quarterly revenue with strong margins. Analysts raised price targets, with an average near $870. REGN's balance sheet and pipeline support its growth prospects.

timothysykes.com4 min
OCT 30
$REGNHighAI 9/10

REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up

Regeneron Pharmaceuticals reported Q3 2026 adjusted EPS of $20.07, beating estimates. Revenue rose 36% YoY to $5.12B, driven by Dupixent, Eylea HD, and Libtayo. Eylea HD sales grew 62% YoY, while legacy Eylea declined 41%. Collaboration revenues surged 52% YoY to $3.00B. The company raised R&D expense guidance but lowered SG&A expense guidance. According to Zacks Investment Research, shares rose on the results.

zacks.com2 min
OCT 30
$REGNHighAI 9/10

Regeneron (REGN) stock trades up, here is why

Regeneron (REGN) shares rose 11.5% after reporting Q3 2026 revenue of $5.1B, up 36%, and EPS of $20.07, up 70%. The company cited record sales for key drugs and expanded its alliance with Sanofi. REGN also announced pipeline milestones and updated trial data for Libtayo. The stock has gained 17.3% YTD, reaching a 52-week high of $910.25.

theglobeandmail.com2 min
OCT 30
$REGNHighAI 9/10

Regeneron Q3 Revenue Rises 36%; Pipeline Advances, FDA Catalysts Ahead; Stock Up

Regeneron reported Q3 2026 revenue of $5.116B, up 36% YoY, with GAAP net income rising 33% to $1.949B. Key products like Dupixent and EYLEA HD saw significant sales growth. The company expanded its Sanofi collaboration, receiving a $1B upfront payment. Regeneron also advanced its pipeline with FDA approvals and positive clinical trial results. The stock is up 11.46%.

rttnews.com3 min